| Literature DB >> 27431387 |
Kosaku Sawada1,2, Masako Fujioka-Kobayashi1, Eizaburo Kobayashi1, Jens O Brömme3, Benoit Schaller1, Richard J Miron4,5.
Abstract
BACKGROUND: High dose radiation therapy is commonly used in maxillofacial surgeries to treat a number of head and neck tumors. Despite its widespread use, little information is available regarding the effects of irradiation on bone cell viability and release of growth factors following dose-dependent irradiation.Entities:
Keywords: Bone cell death; Bone chips; Grays; Growth factor release; Irradiation
Mesh:
Substances:
Year: 2016 PMID: 27431387 PMCID: PMC4948100 DOI: 10.1186/s12903-016-0241-9
Source DB: PubMed Journal: BMC Oral Health ISSN: 1472-6831 Impact factor: 2.757
Fig. 1Scanning electron micrograph (SEM) of control bone samples at magnifications of both 25 times and 400 times. Note the visible protein content found on the surface of bone at a 400 times magnification
Fig. 2Scanning electron micrograph (SEM) of irradiated bone samples at a magnification of 400 times for (a) 7.5, (b) 15, (c) 30, (d) 60 and (e) 120 Grays. Following increasing concentrations of irradiation, little to no changes in the surface homogeneity of proteins could be observed across all irradiated samples
Fig. 3Relative cell viability of bone cells following irradiation at varying concentrations of Grays relative to control samples. Over 85 % of all cells were non-vital in samples receiving as little as 7.5 Gy and all cells were non-vital following 60 Gy. (** denotes significantly higher than all other treatment modalities p < 0.01)
Fig. 4Elisa quantification for growth factors including (a) vascular endothelial growth factor (VEGF), (b) transforming growth factor beta 1 (TGFB1) and (c) bone morphogenetic protein 2 (BMP2). a Following irradiation at all doses, a marked and significant decrease in VEGF was noted at both 15 min and 4 h. b Similarly, TGFB1 had a significant 2 fold decrease at 4 h for irradiated samples. c No changes in BMP2 could be observed at all time points following irradiation. (** denotes significantly higher than all other treatment modalities p < 0.01)
Fig. 5Elisa quantification for growth factors including (a) Receptor activator of nuclear factor kappa-B ligand (RANKL) and (b) interleukin 1-beta (IL1B). a Following irradiation at 4 h, a 2 fold decrease in RANKL could be observed for control samples when compared to all irradiated doses. b No changes in IL1B could be observed at all time points following irradiation. (# denotes significantly lower than all other treatment modalities p < 0.01)